BioCryst预计2025年ORLADEYO销售额为515-535M美元,目的在于获利和获得新的药物批准。 BioCryst expects $515-535M in ORLADEYO sales for 2025, aiming for profitability and new drug approvals.

据生物晶制药公司报告,在2024年,ORLADEYO的收入增加了34%,达到4.37亿美元,预计2025年的收入为5.15至5.35亿美元。 BioCryst Pharmaceuticals reported a 34% increase in ORLADEYO revenue to $437 million in 2024, projecting a 2025 revenue of $515-$535 million. 包括RAPIVAB在内的总收入预计将达到5.4亿至5.6亿美元。 Total revenue, including RAPIVAB, is expected to reach $540-$560 million. 该公司的目标是在2025年年中前实现季度盈利和现金正流动,计划为儿童ORLADEYO颗粒提出新的药物申请,并为Netherton综合症和糖尿病血管水肿预先提供治疗。 The company aims to achieve quarterly profitability and positive cash flow by mid-2025, with plans to file a new drug application for ORLADEYO granules for children and advance treatments for Netherton syndrome and diabetic macular edema.